Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis.

NCT03645499 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.

NCT NCT03645499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03645499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis.
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2018
Completion date
January 7, 2020
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis